Prime Therapeutics Names Glen Laschober as Chief Operating Officer
4/8/2013 11:03:13 AM
ST. PAUL, Minn., April 8, 2013 /PRNewswire/ -- Prime Therapeutics (Prime), a leading pharmacy benefit manager, announced today that it has appointed Glen Laschober as chief operating officer. Laschober will be responsible for developing and implementing the strategic direction for the day-to-day operations of Prime. He will oversee pharmacy benefit management and service operations, information technology, enterprise project planning, and reporting analytics.
"Glen is a seasoned and trusted leader who consistently delivers results," said Eric Elliott, president and CEO at Prime Therapeutics. "I have tremendous confidence in Glen's ability to drive operational excellence across the company and support our continued growth."
Laschober brings to Prime substantial expertise in the health care industry and areas relevant to Prime's strategic growth, specifically specialty pharmacy management. Laschober served as vice president and chief operations officer at US Oncology, the nation's largest oncology company, and Omnicare, a Fortune 500 pharmacy and health care provider. Laschober also held various senior leadership roles at CVS Caremark, Wellinx and ProVantage.
Mostly recently, Laschober was President and CEO at Concorde Career College, where he was instrumental in increasing market revenue and earnings growth.
Laschober earned his Bachelor of Science in Industrial and Manufacturing Engineering from the University of Illinois and his Masters in Business Administration from the University of Chicago.
About Prime Therapeutics
Prime Therapeutics LLC (Prime) helps people get the medicine they need to feel better and live well. Prime manages pharmacy benefits for health plans, employers, and government programs including Medicare and Medicaid. The company processes claims and delivers medicine to members, offering clinical services for people with complex medical conditions. Headquartered in St. Paul, Minn., Prime serves nearly 20 million people. It is collectively owned by 13 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Prime has been recognized as one of the fastest-growing private companies in the nation.
For more information, visit www.primetherapeutics.com or follow @Prime_PBM on Twitter.
SOURCE Prime Therapeutics